Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis
Paul Krogstad, Pearl Samson, Edward P Acosta, Jack Moye, Ellen Townley, Sarah Bradford, Emily Brown, Kayla Denson, Bobbie Graham, Laura Hovind, Thucuma Sise, Hedy Teppler, Sisinyana Ruth Mathiba, Lee Fairlie, Jana L Winckler, Gretchen Slade, Tammy Meyers, International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1101 Team, Paul Krogstad, Pearl Samson, Edward P Acosta, Jack Moye, Ellen Townley, Sarah Bradford, Emily Brown, Kayla Denson, Bobbie Graham, Laura Hovind, Thucuma Sise, Hedy Teppler, Sisinyana Ruth Mathiba, Lee Fairlie, Jana L Winckler, Gretchen Slade, Tammy Meyers, International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1101 Team
Abstract
Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to <2 years receiving concurrent rifampin to treat TB.
Clinical trials registration: NCT01751568.
Keywords: antiretroviral therapy; drug interactions; pediatrics; rifampin; tuberculosis.
© The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Figures
Source: PubMed